Efficacy and acceptability of the new oral phosphate binder Lenziaren® in healthy cats fed a renal diet

Abstract

The efficacy and acceptability of the new oral phosphate binder Lenziaren® (SBR759) were evaluated in healthy cats fed with a commercial diet containing low amounts of phosphate ('renal diet'). Lenziaren® at 0.125, 0.25, 0.5 and 1 g/day was compared to a reference product Lantharenol® (3.0 g/day) and a placebo in a masked, randomized, parallel-group design study in 36 cats (n = 6 per group). All products were mixed with the ration which was fed once daily for 28 days. Lenziaren® produced significant dose-related reductions in serum and urine phosphate concentrations, faecal apparent phosphorus digestibility and fractional urinary phosphate excretion. Cats administered Lenziaren® consumed significantly less food than the placebo group, but this had no negative impact on body weight or acceptability assessments. When compared to the positive control, Lantharenol®, Lenziaren® was significantly more acceptable (0.125, 0.5 and 1.0 g/day doses), was associated with higher food consumption (0.125, 0.5 and 1.0 g/day doses) and had greater efficacy in reducing serum phosphate (0.5 and 1.0 g/day) and urine phosphate concentrations (1.0 g/day). In conclusion, Lenziaren® was an effective oral phosphate binder in healthy cats fed with a renal diet. Lenziaren® was well accepted and tolerated. Dosages of 0.25-1.0 g/cat per day are recommended for clinical testing.